Brief: Aldeyra Therapeutics Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases

Aldeyra Therapeutics

04/01/2024 12:46

Jan 4 (Reuters) - Aldeyra Therapeutics Inc  ALDX.O :
    * ALDEYRA THERAPEUTICS PROVIDES CLINICAL AND REGULATORY
UPDATE AND
ANNOUNCES ADVANCEMENT OF RASP PLATFORM IN SYSTEMIC AND RETINAL
INFLAMMATORY DISEASES
    * ALDEYRA THERAPEUTICS - PHASE 2 CLINICAL TRIAL OF ADX-629
IN
MODERATE ALCOHOLIC HEPATITIS INITIATED; TOP-LINE RESULTS
EXPECTED IN SECOND HALF OF 2024
    * ALDEYRA THERAPEUTICS INC - INVESTIGATIONAL NEW DRUG (IND)
APPLICATION OF ADX-246 SUBMITTED TO FDA FOR PHASE 1 CLINICAL
TRIAL
    * ALDEYRA THERAPEUTICS INC - SPECIAL PROTOCOL ASSESSMENT FOR
CLINICAL TRIAL OF REPROXALAP IN DRY EYE DISEASE AMENDED BASED ON
FDA FEEDBACK

Source text for Eikon:  ID:nBw34Pr1wa 
Further company coverage:  ALDX.O 

 ((Reuters.Briefs@thomsonreuters.com;))